2 weeks Ago By ABMN Staff
Scinai Immunotherapeutics Ltd. ( NASDAQ:SCNI – Get Free Report ) saw a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 11,800 shares, an increase of 16.
8% from the August 31st total of 10,100 shares. Based on an average trading volume of 519,700 shares, the short-interest ratio is currently 0.0 days.
Scinai Immunotherapeutics Trading Down 12.1 % SCNI traded down $0.50 during midday trading on Friday, reaching $3.
64. The company’s stock had a trading volume of 144,750 shares, compared to its average volume of 363,411. Scinai Immunotherapeutics has a 1 year low of $2.
23 and a 1 year high of $9.24. The stock’s 50-day moving average is $3.
84 and its 200-day moving average is $4.08. The firm has a market capitalization of $1.
69 million, a price-to-earnings ratio of -0.01 and a beta of 2.48.
Scinai Immunotherapeutics ( NASDAQ:SCNI – Get Free Report ) last announced its quarterly earnings data on Thursday, August 15th. The company reported ($3.57) earnings per share (EPS) for the quarter.
The business had revenue of $0.28 million during the quarter. About Scinai Immunotherapeutics Scinai Immunotherapeutics Ltd.
, a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. See Also Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
